Effects of warm-up on exercise capacity, platelet activation and platelet–leucocyte aggregation in patients with claudication

Pasupathy, Shanker; Naseem, Khalid M.; Homer‐Vanniasinkam, Shervanthi

doi:10.1002/bjs.4798

Cited by 14 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A sample size of 16 participants per group have 80% power, 5% significance (two‐tailed) to detect one standard deviation score ‘large effect size’ for cIMT between cases and controls. The sample size for platelet function was calculated using the Mann–Whitney U‐ test for continuous data and an ‘effect size’ between 1·12–1·25 . A sample size of 18–20 per group allows us to detect an effect size of 1·12 (or larger) with 80% power, 20% attrition and 5% significance (two‐tailed).…”

Section: Methodsmentioning

confidence: 92%

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity

Kahal

Aburima

Ungvári

et al. 2013

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 92%

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity

Kahal

Aburima

Ungvári

et al. 2013

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The sample size for platelet function was powered using the Mann–Whitney U test for continuous data [ 23 ] and an ‘effect size’ between 1.12–1.25 for changes in P-selectin expression in unstimulated samples [ 24 , 25 ]. A sample size of 18 per group allow us to detect an effect size of 1.12 (or larger) with 80% power, 20% attrition and 5% significance (two-tailed) between cases and controls.…”

Section: Methodsmentioning

confidence: 99%

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

et al. 2015

View full text Add to dashboard Cite

BackgroundPolycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.MethodsCarotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month – baseline) ± standard deviation.ResultsNineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls −0.17 ± 0.26 but not PCOS −0.12 ± 0.28; between groups difference, 95% confidence interval = −0.14 – 0.26, P = 0.41. No significant changes were noted in cIMT or RHI.ConclusionsSix months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3–4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.Trial registrationClinical trial reg. no. ISRCTN48560305. Date of registration 22/05/2012.

show abstract

“…In patients with stable coronary disease, RIC attenuated platelet activation in response to adenosine diphosphate (ADP) and exercise 18 and in patients with claudication, warm-up (a phenomenon akin to IPC) prior to exercise attenuated the exercise-induced increase in platelet-neutrophil and platelet-leukocyte activation. 49 In patients undergoing ablation for atrial fibrillation, RIPC reduced platelet activation in response to ADP, including the formation of monocyteplatelet aggregates. 19 Other studies found that intermittent upper arm IR reduced platelet activation and aggregation in response to ADP in patients with stable angina undergoing angiography or elective angioplasty.…”

Section: Possible Mechanismsmentioning

confidence: 99%

Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial

Gorog

Farag

Spinthakis

et al. 2020

Cardiovascular Research

View full text Add to dashboard Cite

Aims Remote ischaemic conditioning (RIC) has been shown to reduce myocardial infarct size in animal models of myocardial infarction. Platelet thrombus formation is a critical determinant of outcome in ST-segment elevation myocardial infarction (STEMI). Whether the beneficial effects of RIC are related to thrombotic parameters is unclear. Methods and results In a substudy of the Effect of Remote Ischaemic Conditioning on clinical outcomes in STEMI patients undergoing Primary Percutaneous Coronary Intervention (ERIC-PPCI) trial, we assessed the effect of RIC on thrombotic status. Patients presenting with STEMI were randomized to immediate RIC consisting of an automated autoRIC™ cuff on the upper arm inflated to 200 mmHg for 5 min and deflated for 5 min for four cycles (n = 53) or sham (n = 47). Venous blood was tested at presentation, discharge (48 h) and 6–8 weeks, to assess platelet reactivity, coagulation, and endogenous fibrinolysis using the Global Thrombosis Test and thromboelastography. Baseline thrombotic status was similar in the two groups. At discharge, there was some evidence that the time to in vitro thrombotic occlusion under high shear stress was longer with RIC compared to sham (454 ± 105 s vs. 403 ± 105 s; mean difference 50.1 s; 95% confidence interval 93.7–6.4, P = 0.025), but this was no longer apparent at 6–8 weeks. There was no difference in clot formation or endogenous fibrinolysis between the study arms at any time point. Conclusion RIC may reduce platelet reactivity in the first 48 h post-STEMI. Further research is needed to delineate mechanisms through which RIC may reduce platelet reactivity, and whether it may improve outcomes in patients with persistent high on-treatment platelet reactivity.

show abstract

Effects of warm-up on exercise capacity, platelet activation and platelet–leucocyte aggregation in patients with claudication

Abstract: Bradford Scholars -how to deposit your paper Overview Copyright check• Check if your publisher allows submission to a repository.• Use the Sherpa RoMEO database if you are not sure about your publisher's position or email openaccess@bradford.ac.uk.

Cited by 14 publications

References 30 publications

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial

Contact Info

Product

Resources

About